B tier · viable
Graded B for exceptional evidence volume and quality - multiple multi-thousand-patient randomized trials - but held well below A because that same evidence base is what established the FDA boxed warning for death, myocardial infarction, stroke, venous thromboembolism and tumour progression.
epo
Epoetin alfa is a recombinant erythropoiesis-stimulating glycoprotein with an unusually large randomized evidence base that reliably reduces transfusion requirement in defined anaemia populations. That same evidence base produced an FDA boxed warning for increased death, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis and tumour progression, and no trial has identified a haemoglobin target or dosing strategy free of these risks.
the explanation
EPO is a lab-made copy of the kidney hormone that tells bone marrow to make more red blood cells, and it genuinely reduces the need for blood transfusions in some kidney, cancer and HIV patients. Large trials also found it increased deaths, heart attacks, strokes and blood clots when used to push blood counts higher, which is why it carries the FDA's strongest warning.
regulatory status
FDA-approved with a BOXED WARNING; WADA-prohibited at all times
Approved for anaemia of chronic kidney disease, anaemia from zidovudine in HIV-infected patients, anaemia from myelosuppressive chemotherapy, and reduction of allogeneic red cell transfusion in elective non-cardiac, non-vascular surgery. The boxed warning is titled 'WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE' and states that 'No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks.' Contraindicated in uncontrolled hypertension and in PRCA beginning after Epogen. The WADA 2026 Prohibited List names erythropoietins (EPO), darbepoetins, EPO-based constructs and EPO-mimetic agents under S2.
how it works · proposed mechanism
Epoetin alfa is a receptor agonist that expands red cell mass by rescuing erythroid progenitors from programmed cell death.
EPO receptor dimerisation
Binding induces homodimerisation of the erythropoietin receptor on colony-forming-unit erythroid progenitors, activating JAK2 and downstream STAT5, PI3K and MAPK signalling. The dominant effect is anti-apoptotic rather than purely proliferative.
Red cell mass expansion
Surviving progenitors mature into reticulocytes and erythrocytes, raising haemoglobin and haematocrit over days to weeks. This is what reduces transfusion requirement in the approved indications.
Viscosity and thrombotic cost
A higher haematocrit raises whole-blood viscosity and shear-dependent platelet activation, the proposed mechanism for excess arterial, venous and vascular-access thrombosis. The label reports vascular access thrombosis in 8.1% of Epogen-treated dialysis patients versus 2.1% on placebo.
what’s reported
evidence shape
6 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
EPO is one of the most thoroughly randomized compounds in this index, and the trials are precisely what condemn it: four large studies converge on excess mortality, stroke and cardiovascular events when haemoglobin is pushed toward normal. Its benefit is narrow and specific - fewer transfusions in defined anaemic populations - and does not generalise to raising blood counts in healthy people, where the viscosity risk exists without any anaemia to correct.
key published findings
- Human trial (Normal Haematocrit Study): 1,265 dialysis patients with congestive heart failure or coronary artery disease randomized to a haemoglobin target of 14.0 versus 10.0 g/dL; all-cause mortality hazard ratio 1.28 (95% CI 1.06-1.56), with mortality of 35% versus 29%.
- Human trial (CHOIR): 1,432 non-dialysis CKD patients randomized to haemoglobin 13.5 versus 11.3 g/dL; composite cardiovascular hazard ratio 1.34 (95% CI 1.03-1.74), with major cardiovascular events in 18% versus 14%.
- Human trial (TREAT): 4,038 non-dialysis patients with type 2 diabetes randomized to darbepoetin alfa targeting 13.0 g/dL versus placebo; stroke hazard ratio 1.92 (95% CI 1.38-2.68), roughly 5% versus 2.5%, while the primary composite of death or cardiovascular event was not improved (HR 1.05, 95% CI 0.94-1.17).
- Human trial (CREATE, Drueke et al, NEJM 2006;355:2071-2084): 603 CKD patients randomized to haemoglobin 13.0-15.0 versus 10.5-11.5 g/dL; no cardiovascular benefit from normalisation (58 versus 47 first events; HR 0.78, 95% CI 0.53-1.14, P=0.20) and significantly more patients required dialysis in the higher-target group (127 versus 111, P=0.03).
- Human trial (efficacy): in chemotherapy-induced anaemia 14% (25/174) of Epogen-treated adults required transfusion versus 28% (48/170) on placebo; in zidovudine-treated HIV patients with endogenous erythropoietin at or below 500 mUnits/mL, 43% versus 18% became transfusion-independent.
limitations of the evidence
- The large outcome trials tested haemoglobin targets rather than the drug against no drug, so they quantify the harm of over-correction more cleanly than they isolate the intrinsic risk of the molecule at conservative targets.
- TREAT used darbepoetin alfa rather than epoetin alfa, so its stroke signal is extrapolated across the erythropoiesis-stimulating agent class rather than measured for epoetin specifically.
- There is no randomized outcome evidence in non-anaemic people, meaning the entire performance-enhancement use case sits outside the trial literature while inheriting the viscosity mechanism that plausibly drives the observed harms.
documented safety signals
- FDA BOXED WARNING: 'ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE.' The label states that in controlled trials patients experienced greater risks for death, serious adverse cardiovascular reactions and stroke when targeting haemoglobin above 11 g/dL.
- The boxed warning states explicitly that 'No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks' - there is no established safe operating window.
- Oncology: the boxed warning records that ESAs shortened overall survival and/or increased the risk of tumour progression or recurrence in cancer patients.
- Pure red cell aplasia: cases of PRCA and of severe anaemia, with or without other cytopenias, have arisen following development of neutralising antibodies to erythropoietin. Because these antibodies can cross-react with endogenous EPO, the resulting transfusion-dependent anaemia can be effectively irreversible. PRCA beginning after treatment is a contraindication to further use.
- Thrombosis: vascular access thrombosis occurred in 8.1% of Epogen-treated dialysis patients versus 2.1% on placebo; thrombosis generally 2.7% versus 1%. In spinal surgery without anticoagulant prophylaxis DVT occurred in 4.7% versus 2.1%, and the label recommends DVT prophylaxis in surgical use.
- Hypertension: reported in 27.7% of Epogen-treated dialysis patients versus 12.5% on placebo, and 13.7% versus 10.1% in non-dialysis patients. Uncontrolled hypertension is an outright contraindication.
- Seizures: the label states Epogen increases the risk of seizures in patients with chronic kidney disease.
- Doping context: EPO misuse in sport occurs without medical monitoring, without anaemia to correct, and often alongside dehydration and extreme exertion - conditions that compound the haemoglobin-driven viscosity and thrombosis mechanism the trials identified. WADA prohibits EPO receptor agonists at all times, in and out of competition.
- Counterfeit and unregulated EPO carries additional risk of altered glycosylation and aggregation, the manufacturing-related factors historically implicated in antibody-mediated PRCA outbreaks.
identity
| full name | Recombinant Human Erythropoietin (Epoetin Alfa) |
| category | Blood & Oxygen |
| modality | protein hormone |
| molar mass | 30400 g/mol |
| cas | 113427-24-0 |
| half-life | Plasma elimination half-life of 4 to 13 hours after intravenous administration; after subcutaneous administration Cmax is achieved within 5 to 24 hours (Epogen FDA label). |
| sequence | 165-amino-acid recombinant glycoprotein produced in mammalian cell culture, with three N-linked and one O-linked glycosylation sites; not a synthetic linear peptide. |
laboratory handling
| storage | Store at 2-8 C (36-46 F). Do not freeze. Do not shake. Keep vials in the original carton until use to protect from light. |
| solubility | Supplied as a sterile, preservative-free or benzyl-alcohol-preserved aqueous solution for injection; the glycoprotein is water-soluble but denatures on shaking or freezing. |
| co-studied with | The published literature notes that erythropoiesis-stimulating agents require adequate iron stores for a haematological response, and iron status is routinely assessed in the trial protocols. This index does not describe regimens. The material point is that no combination or monitoring strategy identified in any trial removes the boxed-warning risks. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
6 citedU.S. Food and Drug Administration · 2017 · official
World Anti-Doping Agency · 2026 · official
Wiki Journal Club · 2009 · review
New England Journal of Medicine · 2009 · randomized
New England Journal of Medicine 355(20):2071-2084 · 2006 · randomized
New England Journal of Medicine · 2006 · randomized
others in Blood & Oxygen